This article discusses the use of artificial intelligence (AI) in the pathological diagnosis of nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH). NAFLD/NASH is on the rise globally and while non-invasive diagnosis has increased, pathological evaluation remains the gold standard. However, subjective judgment of pathologists can lead to inter-observer variations. AI can assist in diagnosis with high objectivity and accuracy, and several studies have reported its usefulness in NAFLD/NASH diagnosis. The use of AI in human clinical trials is expected in the near future and has the potential to overcome the lack of objectivity and poor inter-observer agreement in pathological diagnosis.
Author(s) Details:
Yoshihisa Takahashi,
Department of Pathology, School of Medicine, International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba 286-8686, Japan.
Erdenetsogt Dungubat,
Department of Pathology, School of Medicine, International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba 286-8686, Japan and Department of Pathology, School of Biomedicine, Mongolian National University of Medical Sciences, Jamyan St 3, Ulaanbaatar 14210, Mongolia.
Hiroyuki Kusano,
Department of Pathology, School of Medicine, International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba 286-8686, Japan.
